Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business and Finance News, In Brief

Executive Summary

Oral Treprostinil Meets Phase III Endpoint

You may also be interested in...



Merck Pulls EPS Guidance To Avoid "Indiscriminate Short-Term Cost Cutting"

In Kenneth Frazier's first financial call as CEO, the exec withdrew Merck's long-term earnings guidance, citing healthcare reform costs, European pricing pressure and a late-stage pipeline setback.

Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut

Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.

Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation

Senate Appropriations Committee proposes $1.185bn to CFSAN and $2.19bn to CDER, both levels short of House appropriators passed in June. FDA requested $30.36m in user fees from monograph drugs but no amount was specified in Senate draft bill.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel